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Abstract
Objective To explore the risk of industry sponsorship bias in a
systematically identified set of placebo controlled and active comparator
trials of statins.
Design Systematic review and network meta-analysis.
Eligibility Open label and double blind randomised controlled trials
comparing one statin with another at any dose or with control (placebo,
diet, or usual care) for adults with, or at risk of developing, cardiovascular
disease. Only trials that lasted longer than four weeks with more than
50 participants per trial arm were included. Two investigators assessed
study eligibility.
Data sources Bibliographic databases and reference lists of relevant
articles published between 1 January 1985 and 10 March 2013.
Data extractionOne investigator extracted data and another confirmed
accuracy.
Main outcome measure Mean absolute change from baseline
concentration of low density lipoprotein (LDL) cholesterol.
Data synthesis Study level outcomes from randomised trials were
combined using random effects network meta-analyses.
ResultsWe included 183 randomised controlled trials of statins, 103 of
which were two-armed or multi-armed active comparator trials. When
all of the existing randomised evidence was synthesised in network
meta-analyses, there were clear differences in the LDL cholesterol
lowering effects of individual statins at different doses. In general, higher
doses resulted in higher reductions in baseline LDL cholesterol levels.
Of a total of 146 industry sponsored trials, 64 were placebo controlled
(43.8%). The corresponding number for the non-industry sponsored
trials was 16 (43.2%). Of the 35 unique comparisons available in 37
non-industry sponsored trials, 31 were also available in industry
sponsored trials. There were no systematic differences in magnitude
between the LDL cholesterol lowering effects of individual statins
observed in industry sponsored versus non-industry sponsored trials.
In industry sponsored trials, the mean change from baseline LDL
cholesterol level was on average 1.77 mg/dL (95% credible interval
−11.12 to 7.66) lower than the change observed in non-industry
sponsored trials. There was no detectable inconsistency in the evidence
network.
ConclusionsOur analysis shows that the findings obtained from industry
sponsored statin trials seem similar in magnitude as those in non-industry
sources. There are actual differences in the effectiveness of individual
statins at various doses that explain previously observed discrepancies
between industry and non-industry sponsored trials.
Introduction
There is concern that the vast majority of published medical
research findings may be false, irrespective of study design.1
Although randomised trials are typically placed at the top of
evidence hierarchies,2 causal inferences from such trials can be
jeopardised by limitations in methodological quality in their
design, conduct, analysis, and reporting, leading to
underestimation or overestimation of the true intervention effect,
that is, bias.3-7 An important source of potential bias relates to
the influence of pharmaceutical industry sponsorship on the
trial findings. Previous reviews showed that industry sponsored
research is more likely to favour the product developed by the
company sponsoring the research than research funded by other
sources.8-10
Statins, a lipid lowering class of drugs, are an interesting case
study for exploring industry sponsorship bias. They are among
the most widely prescribed classes of drugs due to their benefits
in prolonging survival by reducing the risk of coronary and
cerebrovascular events. Clinical practice guidelines in the United
Correspondence to: H Naci h.naci@lse.ac.uk
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States and United Kingdom have considerably lowered the
threshold for receiving statins, potentially increasing the number
of patients eligible to receive the drugs by millions.11-13 Not all
statins are the same: recent comparative analyses synthesising
the placebo controlled and active comparator randomised trials
of individual statins established some statin dose combinations
as more efficacious and tolerable than others.14-17 If present,
industry sponsorship bias may render the findings of such
comparative assessments invalid.18 Indeed, head-to-head
comparisons of statins were shown to be more likely to report
results and conclusions favouring the sponsor’s product
compared with the comparator drug, suggesting the presence
of industry sponsorship bias.19
There are three potential explanations for the observed
relationship between industry sponsorship and trial outcomes.
First, pharmaceutical companies may introduce bias into
individual randomised controlled trials. Second, pharmaceutical
companies may ask the “right” questions and preferentially
sponsor or report trials on a drug that they expect to be superior
to its alternatives.8 This phenomenon, commonly termed design
bias, refers to planning or reporting trials in such a way that
their findings likely favour the sponsored product.20 Third, it is
possible that industry sponsored trials are unbiased: the
effectiveness of different drugs at different doses may indeed
vary, making it difficult to distinguish between a genuine
industry bias and actual differences in treatment effectiveness.
Empirical evidence for an industry sponsorship bias would show
that industry sponsored trials produce systematically different
findings compared with those obtained from identical (or at
least comparable) trials funded by non-industry sources.21
However, such comparability has not been established: the
existing body of literature did not take into account the important
differences in drug interventions, patient populations, and dosing
regimens across industry and non-industry sponsored studies.
In addition, the analyses demonstrated a statistical association
between industry sponsorship and trial conclusions, rather than
differences in the magnitude of effect sizes between industry
sponsored trials and non-industry sponsored trials.22 Currently,
it is not clear by which mechanism industry sponsorship bias
would operate, and how it would influence a complex evidence
network including a large number of placebo controlled and
active comparator trials.
By accounting for dose and treatment differences across trials,
network meta-analysis provides a methodological framework
for evaluating industry sponsorship bias.23 Using statins as an
example, the objective of our study was to explore the
methodological quality and risk of industry sponsorship bias in
a systematically identified set of placebo controlled and active
comparator trials of statins.
Methods
Study identification and selection
We searched Medline, Embase, Cochrane Database of
Systematic Reviews, and Cochrane Central Register of
Controlled Trials between 1 January 1985 and 10 March 2013
using the search terms atorvastatin, fluvastatin, simvastatin,
lovastatin, pravastatin, rosuvastatin, cholesterol, cardiovascular
disease, and hydroxymethylglutaryl-CoA reductase
inhibitors/therapeutic use.We supplemented electronic database
searches by manually cross checking reference lists from
published trials and review articles. Two researchers
independently performed abstract, title, and full text screening.
A third researcher approved study selection.
As described previously,14-17we included open label and double
blind randomised controlled trials comparing one statin with
another at any dose or with control (placebo, diet, or usual care)
for adults with, or at risk of developing, cardiovascular disease.
We included both fixed dose and titration trials of atorvastatin,
fluvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin
if they had more than 50 participants per trial arm, lasted longer
than four weeks, and reported changes from baseline low density
lipoprotein (LDL) cholesterol concentration. In accordance with
predefined criteria,24 we excluded trials conducted in patients
with renal insufficiency.
The primary outcome of interest was the difference in mean
change from baseline in serum LDL cholesterol concentration
between two comparator treatments for a given dose (change
from baseline in the treatment group minus that in the control
group).We extracted information on trial and patient population
characteristics, and the outcome of interest. We extracted the
total number of randomly assigned participants unless only a
subsample of patients were eligible for statin therapy; this was
the case in some of the large trials, which measured LDL
cholesterol levels only in a subsample of the original trial
population. One researcher extracted data and another
independently checked for accuracy.
Categorisation of potential bias
We explored two sources of bias. First was quality related bias,
which we defined as the potential underestimation or
overestimation of the true intervention effect due to flaws in the
methodological attributes of randomised controlled trials.3
Second, we explored industry sponsorship bias, which could
occur when a pharmaceutical sponsor favoured its own drug in
placebo controlled or active comparator trials or the highest
dose of its own drug in dose comparator trials.23
To evaluate quality related bias, we extracted data on the
methodological quality of included randomised trials at the
study level.3Our assessment of methodological quality included
published trial protocols when such documents were cited in
the original trial publications. Using the risk of bias tool
developed by the Cochrane Collaboration,25 we collected
information on blinding (that is, did the investigators blind trial
participants and researchers from knowledge of which treatment
a trial participant received?); random sequence generation (that
is, were the methods for allocation sequence reported to
determine whether it produced comparable groups?); allocation
concealment (that is, were the methods used to conceal the
allocation sequence reported to determine whether group
allocations could have been foreseen before or during
randomisation?); blinding of outcome assessment (that is, did
trial investigators blind outcome assessment from knowledge
of which intervention a participant received?); indications of
incomplete outcome data (that is, did the investigators report
completeness of outcome data for LDL cholesterol lowering,
including attrition and exclusions from the analysis?); and
indications of selective reporting (that is, did the investigators
fail to report tolerability and harm outcomes commonly reported
in randomised trials of statins (such as withdrawals due to
adverse events, creatine kinase elevations, hepatic transaminase
elevations, or myalgia), and were there deviations in trial
outcomes from published protocols?). On each methodological
attribute, we gave studies a rating of high, low, or uncertain
quality. For each trial, we assigned one point for each item with
“high quality” to calculate the overall methodological quality
score, ranging from 0 (worst methodological quality) to 6 (best
methodological quality). Using this information, we evaluated
the distribution of methodological quality of different
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comparisons across the evidence network (for example, explored
whether trials of simvastatin v control had on average higher or
lower methodological quality than those of atorvastatin v
rosuvastatin).
We then extracted information on the funding sources of
included trials. Two potential funding sources were industry
and non-industry (such as government, academic institutions,
other not for profit research organisations). Industry sources
included any private, for profit, pharmaceutical company
involved in research and development, manufacturing, or
marketing of statins. Most of the included trial publications
contained a statement delineating the funding sources; in cases
where sponsorship information was not clearly documented,
we checked the author affiliations and categorised the studies
with industry affiliated authors as industry sponsored. Trials
with industry, government, and/or academic institution
co-sponsorship were categorised as industry sponsored (unless
the trial investigators included a statement that the funding body
had no involvement in trial design, conduct, analysis, or
reporting).
To explore the presence of design bias, we compared the
percentage of industry sponsored trials with placebo controls
with the corresponding percentage in non-industry sponsored
trials. In addition, we compared the type of drug and dose
comparisons between industry and non-industry sponsored trials.
We considered industry sponsored trials where investigators
included a statement that the funding body had no involvement
in trial design, conduct, analysis, or reporting as industry
sponsored for the evaluation of design bias.
Finally, we identified which statin (at a specific dose) was
favoured in a given trial. For the exploration of industry
sponsorship bias, we had two a priori hypotheses (scenarios 1
and 2). Our first hypothesis (scenario 1) was that a
pharmaceutical sponsor would favour its own drug in placebo
controlled or active comparator trials of statins or the highest
dose of its own drug.26 Accordingly, we labelled one arm per
trial as potentially biased in the industry sponsored trials of
statins. In scenario 2, we hypothesised that a sponsor would
favour its own drug in placebo controlled or active comparator
trials of statins, but that it would not differentiate between
different doses of its own drug in dose comparator trials.
Accordingly, we labelled one arm per trial as potentially biased
in the industry sponsored trials of statins unless a given trial
compared the same statin at different doses.
Statistical analysis
We used a network meta-analytic approach to examine the
methodological quality and risk of industry sponsorship bias in
the randomised trials of statins. By taking into account actual
differences in the effectiveness of individual statins at different
doses, network meta-analysis provides an analytic framework
for the exploration of bias.23 We evaluated both the
methodological quality and risk of bias on the basis of the mean
change from baseline in serum LDL cholesterol levels between
two comparator treatments for a given dose (change from
baseline in the treatment groupminus that in the control group).
To determine the dose comparative effects of individual statins,
we simultaneously combined the direct within-trial comparisons
between two treatments (such as atorvastatin at 10 mg/day v
control) with indirect comparisons from trials that had one
treatment in common (such as atorvastatin ≤10mg/day v control
and simvastatin ≤10 mg/day v control).27-29 When combining
direct and indirect evidence, the likelihood for each trial was
based on the mean LDL cholesterol change from baseline in
each treatment arm and its variance. The information on any
multi-arm trial was used in the network meta-analysis just once,
thereby correctly informing all treatment contrasts while also
correctly taking into account the between-arm correlations in
multi-arm trials.30 This analysis preserved the within-trial
randomised treatment comparison of each trial while combining
all available comparisons between treatments across trials. We
combined study-level relative treatment effects using bayesian
Markov chain Monte Carlo methods in WinBUGS version
1.4.3.31 We used the model developed by Dias and colleagues
for the National Institute of Health and Care Excellence (NICE)
Decision Support Unit,30 32 33 assuming that the mean change
from baseline in LDL cholesterol per trial arm had a normal
distribution. We used the identity function to link the relative
effects across trials making different comparisons, while taking
into account the correlations between treatment effects within
multi-arm trials. All analyses were dose-specific and explored
the effects of individual statins at different doses separately.
Accordingly, we did not assume any trends and treatment effects
at different doses were not “nested” within an overall treatment
effect for each statin.
Our models adopted both fixed and random effects for dose
comparative treatment effects.34 The fixed effect model assumed
that there was no between-study heterogeneity. The random
effects model took into account potential heterogeneity by
assuming that the trial-specific treatment effects were drawn
from a distribution, with a mean that was specific for each
treatment, and a common variance shared by all treatments. Our
bayesian models adopted non-informative prior distributions
for treatment effects (normal (0, 10 000)) and the between-trial
variance (uniform (0, 100)) in random effects analyses. We
tested the sensitivity of our analyses to prior distributions by
examining whether the effect sizes and credibility intervals
changed after usingmore informative priors for the between-trial
variance in random effects models (uniform (0, 10)).
To qualitatively evaluate the sensitivity of our base case analyses
to study-level methodological quality attributes, we carried out
six sets of separate network meta-analyses by excluding studies
with low quality on the following methodological items: (1)
blinding of patients and investigators; (2) random sequence
generation; (3) allocation concealment; (4) blinding of outcome
assessment; (5) indications of incomplete outcome data; and
(6) indications of selective reporting. We subsequently plotted
side by side the treatment effect sizes and 95% credible intervals
obtained from each of the six separate analyses and visually
inspected any potential discrepancies.
To evaluate potential industry sponsorship bias, we carried out
meta-regression analyses.26 35 36 We performed all
meta-regression analyses by allowing for a common treatment
bias interaction for each statin dose compared with control.37 In
addition to assuming that each trial estimated a study-specific
bias, which came from a common bias distribution (that is,
random effects model for bias), in a separate analysis we also
assumed that all studies estimated the same bias parameter (that
is, fixed effect model for bias).
To evaluate inconsistency between direct and indirect evidence,
we first qualitatively evaluated the consistency of relative
treatment effects obtained from an analysis of active comparator
trials (that is, direct evidence) with those obtained from an
analysis combining both placebo controlled and active
comparator trials (that is, mixed evidence). We plotted and
visually inspected the relative treatment effects obtained from
two sets of analyses (that is, direct and mixed estimates) and
found no discernible evidence of inconsistency. As we
previously reported,16 there was also no evidence that the
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potential heterogeneity and inconsistency across the evidence
base could be explained by baseline mean age, baseline mean
LDL cholesterol concentration, or publication year.
Our analyses employed a long burn-in period (50 000 iterations)
and follow-up period (80 000-100 000 iterations) to allow for
convergence. We visually inspected trace plots for key
parameters for each analysis to assess convergence in terms of
stability. We formally evaluated the goodness of fit of our
models using the total residual deviance (posterior mean of the
deviance under a given model minus the deviance for the
saturated model) along with the deviance information criterion
(sum of the posterior mean of the residual deviance and the
effective number of parameters).32Because of better fit, we only
reported the results obtained from the fixed effect model for
bias and random effects model for treatment effects; the total
residual deviance for the fixed effect model for bias and random
effects model for treatment effects was 228.20 as compared
with 229.20 for the random effects model for both bias and
treatment effects.
Results
Characteristics of eligible trials
We included 183 randomised controlled trials of statins (fig
1⇓). Most of the eligible trials included active comparators:
there were 80 two-armed placebo controlled trials as compared
to 103 two-armed or multi-armed active comparator trials (see
table 1 in web appendix). There were 53 trials conducted among
individuals with established coronary heart disease; 41 trials
investigated primary prevention (nine of which were among
individuals with diabetes); 10 included patients with acute
coronary syndrome; four included patients with metabolic
syndrome; and three were among patients with heart failure.
The remaining 72 trials included individuals with
hypercholesterolaemia with or without established coronary
heart disease.
Figure 2⇓ shows the network of eligible statin and dose
comparisons for the base case network meta-analysis.
Atorvastatin and rosuvastatin at various doses were compared
most often (n=61), followed by pravastatin and placebo (n=35),
simvastatin and placebo (n=18), and atorvastatin and placebo
(n=24). There were no comparisons between fluvastatin and
rosuvastatin or between lovastatin and rosuvastatin at any dose
formulation.
Methodological quality of included trials
Out of a total of 183 trials, 112 were double blind (rated as high
quality) while 58 were open label and two were single blind
(rated as low quality). Blinding was not clear for the remaining
11 trials. Fifty four of the included trials were rated as high
quality in terms of random sequence generation; the
corresponding numbers were 24 for allocation concealment; 70
for blinding of outcome assessment; 95 for incomplete outcome
data; and 127 for selective reporting. A large number of trials
were considered to have unclear methodological quality: 94
trials for random sequence generation; 77 for allocation
concealment; 46 for blinding of outcome assessment; 48 for
incomplete outcome data; and 11 for selective reporting.
On average, the included set of trials had between two and three
methodological attributes with high quality (average
methodological quality score across the included set of trials
was 2.65). Fourteen trials did not have any methodological
attributes with high quality; 38 trials had one; 37 had two, 38
had three; 30 had four; and 14 had five. Only 11 trials were
rated as having high quality on all six methodological quality
attributes.
Distribution of methodological quality in the
evidence network
Figure 3⇓ shows the available comparisons between individual
statins and control. The majority of comparisons had an average
methodological score between two and three. On average,
placebo controlled trials of rosuvastatin and simvastatin had
higher methodological quality than other comparisons (average
methodological quality score for both comparisons >3). Trials
comparing atorvastatin and fluvastatin (two trials, average
methodological quality score 1.50); atorvastatin and rosuvastatin
(34 trials, score 1.97); atorvastatin and simvastatin (24 trials,
score 1.79); fluvastatin and pravastatin (one trial, score 1.00);
fluvastatin and simvastatin (two trials, score 1.30); lovastatin
and simvastatin (three trials, score 1.66); and pravastatin and
simvastatin (10 trials, score 1.80) were rated as having very low
methodological quality.
Influence of methodological quality attributes
on dose comparative effects
Figure 4⇓ shows the sensitivity of the dose comparative effects
of individual statins to different trial-level methodological
quality attributes. Overall, the results based on high quality trials
seemed similar to all other trials. When the findings of six
separate network meta-analyses were visually inspected side
by side, the magnitude of the LDL cholesterol lowering effect
of individual statins was qualitatively similar. The effect size
tended to get smaller in sensitivity analyses that included only
trials with highmethodological quality attributes. In cases where
there were few data points available (for example, fluvastatin
at all dose formulations, lovastatin at ≤10 mg/day, and
pravastatin at >40 mg/day), there was considerable uncertainty
(wide 95% credible intervals) around the observed treatment
effects in sensitivity analyses. In all analyses, 95% credible
intervals greatly overlapped across base case and sensitivity
analyses.
Evaluation of industry sponsorship bias
A total of 146 randomised trials were sponsored by the
pharmaceutical industry, and 37 trials were sponsored by
governmental agencies, academic research centres, and other
not-for-profit organisations. Of the 146 industry sponsored trials,
64 were placebo controlled (43.8%). The corresponding number
for the non-industry sponsored trials was 16 (43.2%). There
were 33 multi-armed industry sponsored trials, compared with
six multi-armed non-industry sponsored trials. Of a total of 59
statin and dose comparisons available in the 37 non-industry
sponsored trials (includingmultiple comparisons in multi-armed
trials), 35 were unique comparisons, and 31 of the unique
comparisons were also available in the industry sponsored trials
(see table 2 in web appendix).
There were no systematic differences between the findings
obtained from industry sponsored and non-industry sponsored
trials (fig 5⇓). There were differences in the LDL cholesterol
lowering effects of individual statins at different doses. In
general, higher doses resulted in greater reductions in baseline
LDL cholesterol levels (fig 5). While the network meta-analysis
of industry sponsored trials estimated a larger treatment effect
for some statin dose combinations as compared with the network
meta-analysis of non-industry sponsored trials, the opposite was
true in other cases. There was generally greater uncertainty
around the cholesterol lowering effects of individual statins in
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non-industry sponsored trials, reflecting the smaller number of
randomised controlled trials that were funded by non-industry
sources. Overall, point estimates and 95% credible intervals
greatly overlapped for all statin dose combinations included in
both sets of network meta-analyses.
Figure 6⇓ shows the magnitude of mean industry sponsorship
bias, as obtained from the meta-regression analysis. There was
no clear evidence of industry sponsorship bias: the mean change
from baseline LDL cholesterol levels was on average 1.77
mg/dL with very wide credible intervals (−11.12 to 7.66) lower
in scenario 1 and 1.66 mg/dL (−11.27 to 7.91) in scenario 2.
Discussion
The Cochrane Collaboration defines bias as a systematic
deviation from the truth, in results or inferences of studies.25 In
other words, bias refers to systematic error, suggesting that
multiple replications of the same trial would reach the wrong
answer on average. Although randomised research designs are
largely immune to many biases that affect weaker forms of
evidence obtained from nonrandomised studies, important
deficits in the design, conduct, analysis, and reporting may still
lead to bias in randomised controlled trials.3 Consistent with
the literature evaluating the risk of bias due to reported design
characteristics of randomised trials,38 39 our study did not detect
any effect of trial-level methodological flaws on objective
laboratory outcomes such as reduction in serumLDL cholesterol
concentration.
There is now a long history of studies evaluating industry
sponsorship bias. These studies unequivocally conclude that
industry sponsorship biases study outcomes in favour of the
sponsoring company’s product.8-10 40-42 Previous reviews have
outlined a number of potential mechanisms by which industry
sponsors can influence the outcome of a study, including how
the trial is designed, conducted, analysed, and reported. Given
the conclusive evidence that the methodological quality of
industry sponsored trials is at least as good as (and often better
than) those sponsored by non-industry sources,40 the observed
discrepancies may be attributable to factors that cannot be
explained by standard tools for assessment of risk of bias.
Unlike the findings of previous studies,19 our analysis did not
find empirical evidence of industry sponsorship bias in a
systematically identified set of placebo controlled and active
comparator trials of statins. First, the mean change from baseline
LDL cholesterol levels achieved in industry sponsored trials
closely paralleled in magnitude the reductions observed in
non-industry sponsored trials: there was no evidence that
pharmaceutical sponsors favoured their own drugs in placebo
controlled or active comparator trials of statins. There were
actual differences in the effectiveness of individual statins at
different doses that,16 when taken into account, explained
previously observed differences between industry and
non-industry sponsored trials. Second, a similar share of industry
and non-industry sponsored statin trials was placebo controlled.
In addition, out of a total of 35 unique statin dose comparisons
available in non-industry sponsored trials, 31 were also available
in industry sponsored trials.
Our assessment of industry sponsorship bias differed from
previous reviews in the literature in three important ways. First,
we paid particular attention to the comparability of patient
populations, interventions, and doses across the identified set
of trials.21 Our review adopted mean reduction in LDL
cholesterol concentration from baseline as the primary outcome
of interest for two important reasons. First, mean LDL
cholesterol reduction from baseline was the most commonly
reported outcome in the randomised controlled trials of statins.
Second, LDL cholesterol reduction is an objective laboratory
outcome, which is largely immune to biases resulting from
deficits in methodological quality in randomised controlled
trials.38 39 It would not be possible to distinguish industry
sponsorship bias from other design related biases if our models
were based on other, more subjective outcomes such as
myocardial infarctions.
Second, we explored the mechanism of potential bias. It is
difficult to determine how industry biases frommultiple funding
sources would influence a complex body of evidence, with
different pharmaceutical companies sponsoring different
products.22 We tested the hypothesis that industry sponsorship
bias would occur when a pharmaceutical sponsor favoured its
own product in placebo controlled or active comparator trials,
or the highest dose of its own drug in a trial comparing multiple
doses. Based on these analyses, there was no evidence that the
pharmaceutical companies intentionally favoured their products
in the randomised controlled trials of statins.
Third, our analyses took into account actual differences in
effectiveness between individual statins at different doses, and
investigated intervention effect sizes. Previous reviews showed
that there was a statistical association between industry
sponsorship and positive results.8 10 40 Positive results observed
in earlier studies referred to a dichotomous outcome of either
reporting statistically significant findings or positive conclusions
that were favourable for the sponsoring company. However, the
difference in the frequency of either statistically significant
findings or favourable conclusions observed between industry
sponsored and non-industry sponsored trials should not be
referred to as bias. Bias is the underestimation or overestimation
of true intervention effects. Therefore, any bias assessment
would need to evaluate the magnitude of the intervention effect
(as well as its uncertainty). Using network meta-analyses, we
took into account actual effectiveness differences between
individual statins at different doses and evaluated the magnitude
of mean LDL cholesterol reduction from baseline achieved with
individual statins in industry and non-industry sponsored trials,
and showed that the magnitude of effect was not systematically
different—either qualitatively or quantitatively—in the two sets
of trials.
Generalisability of findings
An important consideration is whether our findings are
generalisable to the assessment of industry sponsorship bias in
other therapeutic areas. Certainly, there are unique aspects of
the statin evidence base that complicate comparisons with other
therapeutic areas. First, Lathyris and colleagues previously
suggested that the more favourable results of industry sponsored
trials might be due to design issues, in particular the choice of
comparators with dosing regimens that are either inactive or
suboptimal.43Unlike other therapeutic areas where the influence
of dose on treatment effectiveness may not be widely known
outside of industry researchers, statin drugs have a widely
established dose response relationship with higher doses
resulting in greater cholesterol lowering effects. It is possible
that this relationship might have made it difficult for
pharmaceutical companies to introduce overt design biases in
randomised controlled trials using dose as a design factor.
Second, previous studies have shown that each pharmaceutical
company generates a clinical research agenda that is strongly
focused on its own products, while comparisons involving
interventions from different companies are uncommon.43
However, this was not the case in the clinical literature
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evaluating the effectiveness of statin therapy. There were a large
number of trials where pharmaceutical companies compared
their products against licensed regimens belonging to other
companies.
Potential industry sponsorship bias is among many intertwined
bias domains in the literature. For example, problematic industry
practices in terms of deliberate delays in publication and
withholding data result in significant publication biases.44 45 In
recent years, pharmaceutical companies have attempted to
prevent studies with unfavourable results from being published,
and to publish positive studies with positive results more than
once in high profile cases.46 47 Perpetuating such publication
biases, pharmaceutical companies have been shown to
selectively report favourable outcomes while deliberately hiding
information on others such as harm endpoints.48 Such practices,
which do not seem to be prevalent in the statin literature,14 may
partly explain the previous findings of bias in favour of
outcomes of research funded by industry.46
Bias in an individual trial versus a collection
of trials
Pharmaceutical companies almost exclusively sponsor trials
that have favourable conclusions for its products. Perhaps
unsurprisingly, some companies selectively compare their
products against others that they deem strategic competitors.
For example, all of the direct head-to-head comparisons between
rosuvastatin, which entered the US market in 2003 (sponsoring
company, AstraZeneca), and atorvastatin, which was approved
by the Food and Drug Administration in 1996 (sponsoring
company, Pfizer), were funded by AstraZeneca. In a similar
fashion, Pfizer sponsored the majority of head-to-head trials of
atorvastatin and earlier statins. This seems consistent with the
recent concern voiced by Light and Lexchin, postulating that
much of the research and development activities of
pharmaceutical companies are driven by strategic marketing
and sales motives.49 The industry’s tendency to trial its products
against weaker alternatives may skew the nature of the available
evidence and introduce potential asymmetries; however, doing
so does not mean that the trial results themselves are biased. In
the case of statins, findings obtained from industry sponsored
trials seem similar in magnitude as those from non-industry
sources,
Over the past quarter century, every randomised trial provided
a piece of a puzzle that, when taken together, provided a
relatively symmetric and balanced evidence network for statins
(despite the small number of trials available for some statins
such as fluvastatin and lovastatin). Unlike other therapeutic
fields,50 51 the randomised controlled trial evidence base of statins
included a large number of head-to-head trials providing
information on a range of doses. Nonetheless, there is a risk of
deriving biased conclusions about the comparative effects of
individual statins. For instance, a meta-analysis failing to take
into account dose differences between individual statins would
produce biased results. A better approach is to synthesise the
relevant evidence network, which includes all placebo controlled
and active comparator trials and provide direct and indirect
information for all treatment contrasts of interest at different
doses.14-17
Limitations
The findings from our analysis should be considered in light of
its limitations. First, it is possible that our assessment of the
methodological attributes of included trials could underestimate
their quality. Such assessments have an important shortcoming:
when applied to published accounts of randomised trials, it
becomes very challenging to distinguish between factors that
were missing (such as adequate concealment of treatment
allocation) and those that were simply not reported.
Second, we were unable to base our evaluation of industry
sponsorship bias on other objective and clinically meaningful
outcomes such as all-cause mortality. As trials reporting such
outcomes were almost exclusively funded by the industry, there
was an inadequate number of non-industry sponsored trials for
a meaningful comparison between the two sets of trials. In a
similar fashion, there were few prospectively designed, direct
head-to-head trials of individual statins evaluating all-cause
mortality.
Third, as with any meta-regression analysis, our primary
statistical assessment of industry sponsorship bias had low power
to detect bias and resulted in wide credible intervals.52
Nevertheless, our null finding is unlikely to be attributable to
the low power in the statistical analysis. The side by side
comparison of the LDL cholesterol lowering effects of individual
statins obtained from industry and non-industry sponsored trials
provides compelling evidence that there is no systematic
difference in the LDL cholesterol reduction from baseline
achieved in the two sets of trials evaluating the same sets of
statins at the same doses.
Finally, our analyses share the limitations of the studies included
in our review.Many of the randomised controlled trials included
in our study did not use an analysis of covariance model
(ANCOVA) and instead modelled the changes in LDL
cholesterol levels without adjusting for baseline values. Such
analytic approaches have been shown to produce biased results
in cases where baseline values in different treatment arms are
not balanced, which is particularly the case in small studies.53 54
In accordance with predefined criteria, we excluded randomised
trials with <50 patients per arm to guard against small study
biases, including potential imbalances in baseline levels between
treatment arms.
Conclusion
Despite the previously observed relationship between industry
sponsorship and trial outcomes, we found no evidence of
industry sponsorship bias in a systematically identified set of
placebo controlled and active comparator trials of statins. There
are actual effectiveness differences among different statins at
different doses, which should be considered in future evaluations
of sponsorship bias. Our findings highlight the need for further
research into the empirical basis for industry sponsorship biases.
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Figures
Fig 1 Flow diagram of study identification and selection
Fig 2 Network of available comparisons. Size of node is proportional to number of trial participants, and thickness of line
connecting nodes is proportional to number of participants randomised in trials directly comparing the two treatments
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Fig 3 Network of available comparisons between individual statins and control. Size of node is proportional to number of
trial participants, and thickness of line connecting nodes is proportional to number of participants randomised in trials directly
comparing the two treatments
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Fig 4 Sensitivity of network meta-analysis findings to methodological quality attributes of randomised controlled trials of
statins. In addition to the findings of the base case analysis (blue circles), findings of separate sensitivity analyses are
shown. These excluded trials with low quality on the following methodological quality attributes: blinding (white circles),
random sequence generation (blue squares), allocation concealment (white squares), blinding of outcome assessment
(blue triangles), incomplete outcome data (white triangles), and selective reporting (blue diamonds). Figure shows mean
(95% credible interval) change from baseline low density lipoprotein (LDL) cholesterol concentration with different statins
and doses compared with control; lower (more negative) values favour statin treatment
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Fig 5 Dose comparative effects of statins on serum low density lipoprotein (LDL) cholesterol concentration in industry
sponsored clinical trials versus non-industry sponsored trials. Findings from industry sponsored trials are shown in white
and findings from non-industry sponsored trials are shown in blue. Estimates shown are mean (95% credible interval)
change from baseline serum LDL cholesterol concentration compared with control
Fig 6Meta-regression analysis results: evaluation of industry sponsorship bias in the randomised controlled trials of statins.
In scenario 1 a pharmaceutical sponsor would favour its own drug in placebo controlled or active comparator trials of statins
or the highest dose of its own drug; in scenario 2 a sponsor would favour its own drug in placebo controlled or active
comparator trials of statins, but it would not differentiate between different doses of its own drug in dose comparator trials.
Figure shows the extent to which mean (95% credible interval) change from baseline low density lipoprotein (LDL) cholesterol
concentration was exaggerated in trials with industry favoured statins; lower (more negative) values suggest greater bias.
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